| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -X is attached to only one of the ring nitrogen atoms. X is -Y-[C(R a ) 2 ] a -, where Y is a bond; R a is H; a is 1, 2 or 3. R 1 is: (i) a monocyclic bicyclic heteroaryl having 5 to 6 ring atoms, which is optionally substituted with 1 to 3 R o ; wherein 1-2 ring atoms are a heteroatom independently selected from N and N-R o ; (ii) phenyl which is optionally substituted 1-3 R o ; or (iii) C 3 -C 10 cycloalkyl. R 4 is H. Each variant of R o is independently selected from the group consisting of halogen; C 1 -C 6 alkyl and fluoro(C 1 -C 6 )alkyl. R 5 is hydrogen, R 2 is H and R 3 is H, F or Cl. Invention also relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, methods for inhibiting said enzymes using a compound of formula (I) and methods for treating diseases mediated by said enzymes. (I). n EFFECT: compound of formula (I) inhibits histone deacetylase (HDAC) enzymes, for example HDAC1, HDAC2 and HDAC3. n 40 cl, 5 tbl, 1 ex |